摘要
目的:探讨酒精和在一组阿尔茨海默氏病(AD)患者的认知能力下降之间的关系,包括量和类型。 方法:在纽约,波士顿,巴尔的摩和巴黎的360例早期阿尔茨海默氏病患者进行随访,每半年一次到19.28年。在每次访问时,用改良迷你精神状态检查(mMMSE)对患者的认知状况和患者的酒精摄入进行评估,包括饮料类型,是由病人的主要看护人报告。一般使用估计方程分析,以确定是否基线酒精的使用与认知能力下降的速度有关。 结果:重度饮酒者(8次或更多的酒精饮料/周)有一个更快的认知能力下降,与mMMSE戒酒者(P = 0.001)相比,每年恶化1.849%,或与轻中度饮酒者(1-7酒精饮料/周)(P = 0.008)相比,每年恶化2.444%。,比较轻中度饮酒者戒酒者无显着差异。提高硬白酒类标准的饮料,而不是啤酒或葡萄酒,还拥有更快的认知功能下降率相关(β= -0.117 P = 0.001)。 结论:在阿尔茨海默病患者中,大量的酒精消费和更硬的酒与一个更快的认知下降率有关,这表明他们可能会加速进展的阿尔茨海默病。我们的研究结果表明,饮酒习惯可能会改变阿尔茨海默病患者过程。
关键词: 酒精,阿尔茨海默病,认知功能减退,痴呆,疾病进展,烈性酒,流行病学危险因素
Current Alzheimer Research
Title:The Association Between Alcohol Use and the Progression of Alzheimer’s Disease
Volume: 13 Issue: 12
Author(s): Devorah Heymann, Yaakov Stern, Stephanie Cosentino, Oksana Tatarina-Nulman, Jhedy N. Dorrejo, Yian Gu
Affiliation:
关键词: 酒精,阿尔茨海默病,认知功能减退,痴呆,疾病进展,烈性酒,流行病学危险因素
摘要: Objective: To examine the relationship between alcohol, both the amount and type, and cognitive decline in a cohort of Alzheimer’s disease (AD) patients.
Methods: A cohort of 360 patients with early AD in New York, Boston, Baltimore and Paris were followed-up biannually for up to 19.28 years. At each visit, the cognitive profile of the patients was assessed using the modified Mini-Mental State Examination (mMMSE), and patients’ alcohol intake, including beverage type, was reported by patients’ primary caregivers. General estimating equation analysis was used to determine whether baseline alcohol use was associated with the rate of cognitive decline.
Results: Heavy drinkers (8 or more alcoholic drinks/week) had a faster cognitive decline, deteriorating 1.849 more points on their mMMSE score annually compared to abstainers (P = 0.001), or 2.444 more points compared to mild-moderate drinkers (1-7 alcoholic drinks/week) (P = 0.008). There was no significant difference when comparing mild-moderate drinkers to abstainers. Increasing standard drinks of hard liquor, but not beer or wine, was also associated with a faster rate of cognitive decline (β = -0.117 P = 0.001).
Conclusion: Heavy alcohol consumption and more hard liquor are associated with a faster rate of cognitive decline in AD patients, suggesting that they may hasten progression of AD. Our results suggest that alcohol drinking habits might alter the course of AD.
Export Options
About this article
Cite this article as:
Devorah Heymann, Yaakov Stern, Stephanie Cosentino, Oksana Tatarina-Nulman, Jhedy N. Dorrejo, Yian Gu , The Association Between Alcohol Use and the Progression of Alzheimer’s Disease, Current Alzheimer Research 2016; 13 (12) . https://dx.doi.org/10.2174/1567205013666160603005035
DOI https://dx.doi.org/10.2174/1567205013666160603005035 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Histone Deacetylase Inhibitors as Potent Modulators of Cellular Contacts
Current Drug Targets Target-oriented Mechanisms of Novel Herbal Therapeutics in the Chemotherapy of Gastrointestinal Cancer and Inflammation
Current Pharmaceutical Design Opioid Receptor Interacting Proteins and the Control of Opioid Signaling
Current Pharmaceutical Design Apoptosis-related BCL2-family Members: Key Players in Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Real Time Analysis of Neurotransmitters in the Brain Using a Micro-Electrode System
Current Neurovascular Research Imaging of EGFR and EGFR Tyrosine Kinase Overexpression in Tumors by Nuclear Medicine Modalities
Current Pharmaceutical Design The Role of Iron Toxicity in Oxidative Stress-induced Cellular Degeneration in Down Syndrome: Protective Effects of Phenolic Antioxidants
Current Nutrition & Food Science Monoclonal Antibodies in the Treatment of Neuroimmunological Diseases
Current Pharmaceutical Design Preclinical Evaluation of no-Carrier-Added [131I]Meta-Iodobenzyl Guanidine, for the Treatment of Tumours Transfected with the Noradrenaline Transporter Gene
Letters in Drug Design & Discovery Metabolic Aspects of Prion Diseases: An Overview
Current Drug Targets Atypical PKCι as Target for Glioblastoma Therapy
Current Cancer Drug Targets The Polyhedric Abl Kinases and their Pharmacologic Inhibitors
Current Enzyme Inhibition Infectious Agents and Neurodegenerative Diseases: Exploring the Links
Current Topics in Medicinal Chemistry Inhibition of Tau Protein Aggregation by Rhodanine-based Compounds Solubilized Via Specific Formulation Additives to Improve Bioavailability and Cell Viability
Current Alzheimer Research Apoptosis in Drug Response
Current Pharmacogenomics Involvement of Trace Elements in the Pathogenesis of Prion Diseases
Current Pharmaceutical Biotechnology Novobiocin and Additional Inhibitors of the Hsp90 C-Terminal Nucleotide- binding Pocket
Current Medicinal Chemistry The Mechanism of Memory Impairment Induced by Aβ Chronic Administration Involves Imbalance between Cytokines and Neurotrophins in the Rat Hippocampus
Current Alzheimer Research Therapeutic Use of Agonists of the Nuclear Receptor PPARγ in Alzheimers Disease
Current Alzheimer Research Targeted Toxins for Glioblastoma Multiforme: Pre-Clinical Studies and Clinical Implementation
Anti-Cancer Agents in Medicinal Chemistry